PL2365987T3 - Przeciwciała anty-HER4 swoiste dla określonej izoformy - Google Patents

Przeciwciała anty-HER4 swoiste dla określonej izoformy

Info

Publication number
PL2365987T3
PL2365987T3 PL09760430T PL09760430T PL2365987T3 PL 2365987 T3 PL2365987 T3 PL 2365987T3 PL 09760430 T PL09760430 T PL 09760430T PL 09760430 T PL09760430 T PL 09760430T PL 2365987 T3 PL2365987 T3 PL 2365987T3
Authority
PL
Poland
Prior art keywords
specific anti
isoform specific
her4 antibodies
her4
antibodies
Prior art date
Application number
PL09760430T
Other languages
English (en)
Inventor
Mark X Sliwkowski
Klaus Elenius
Maija Hollmen
Original Assignee
Genentech Inc
Univ Of Turku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Univ Of Turku filed Critical Genentech Inc
Publication of PL2365987T3 publication Critical patent/PL2365987T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09760430T 2008-11-25 2009-11-24 Przeciwciała anty-HER4 swoiste dla określonej izoformy PL2365987T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11790308P 2008-11-25 2008-11-25
PCT/US2009/065712 WO2010068437A1 (en) 2008-11-25 2009-11-24 Isoform specific anti-her4 antibodies
EP09760430.0A EP2365987B1 (en) 2008-11-25 2009-11-24 Isoform specific anti-her4 antibodies

Publications (1)

Publication Number Publication Date
PL2365987T3 true PL2365987T3 (pl) 2015-04-30

Family

ID=42021645

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09760430T PL2365987T3 (pl) 2008-11-25 2009-11-24 Przeciwciała anty-HER4 swoiste dla określonej izoformy

Country Status (15)

Country Link
US (2) US20110293614A1 (pl)
EP (1) EP2365987B1 (pl)
JP (1) JP5894436B2 (pl)
KR (1) KR101789338B1 (pl)
CN (2) CN102725310A (pl)
AU (1) AU2009324939B2 (pl)
BR (1) BRPI0916092A2 (pl)
CA (1) CA2744512C (pl)
DK (1) DK2365987T3 (pl)
ES (1) ES2528929T3 (pl)
IL (1) IL212900A0 (pl)
MX (1) MX2011005382A (pl)
PL (1) PL2365987T3 (pl)
SI (1) SI2365987T1 (pl)
WO (1) WO2010068437A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102725310A (zh) 2008-11-25 2012-10-10 健泰科生物技术公司 同等型特异性抗her4抗体
US10083108B1 (en) * 2017-12-18 2018-09-25 Clover Network, Inc. Automated stack-based computerized application crawler
CN112753956A (zh) * 2021-01-20 2021-05-07 重庆周师兄餐饮文化有限公司 一种腰片的加工方法
CN113999228B (zh) * 2021-11-08 2022-11-04 南京卓康医药科技有限公司 一种他达拉非的合成方法
CN119823275A (zh) * 2023-10-12 2025-04-15 徕特康(苏州)生物制药有限公司 抗her4抗体及其制备方法和用途
CN119823276A (zh) * 2023-10-12 2025-04-15 徕特康(苏州)生物制药有限公司 抗her4抗体及其制备方法和用途
CN119823274A (zh) * 2023-10-12 2025-04-15 徕特康(苏州)生物制药有限公司 抗her4抗体及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
AU9805398A (en) * 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
CN102725310A (zh) 2008-11-25 2012-10-10 健泰科生物技术公司 同等型特异性抗her4抗体

Also Published As

Publication number Publication date
US20160075798A1 (en) 2016-03-17
AU2009324939A1 (en) 2010-06-17
AU2009324939B2 (en) 2015-07-09
ES2528929T3 (es) 2015-02-13
US9963517B2 (en) 2018-05-08
CA2744512A1 (en) 2010-06-17
WO2010068437A1 (en) 2010-06-17
CN109608545A (zh) 2019-04-12
JP2012509896A (ja) 2012-04-26
US20110293614A1 (en) 2011-12-01
CA2744512C (en) 2018-05-15
MX2011005382A (es) 2011-07-20
KR101789338B1 (ko) 2017-10-23
BRPI0916092A2 (pt) 2015-11-17
EP2365987A1 (en) 2011-09-21
SI2365987T1 (sl) 2015-03-31
JP5894436B2 (ja) 2016-03-30
CN102725310A (zh) 2012-10-10
DK2365987T3 (en) 2015-01-12
EP2365987B1 (en) 2014-11-12
KR20110098756A (ko) 2011-09-01
IL212900A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
IL212175B (en) Muc1* antibodies
SMT201600288B (it) SPECIFICI ANTICORPI IgE
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
EP2254911A4 (en) HUMANIZED ANTI-C5aR ANTIBODIES
PT2406284T (pt) Anticorpos anti-bcma
EP2262831A4 (en) ANTI-properdin antibody
EP2482848A4 (en) Endoglin antibodies
HUE056626T2 (hu) Antitestkészítmény
BRPI0923359A2 (pt) Anticorpos anti-igf
HRP20150224T1 (xx) Anti-mif protutijela
EP2351777A4 (en) ANTI-MUC1 ANTIBODIES
EP2340256A4 (en) IMPROVED ANTIBODY LIBRARIES
EP2358392A4 (en) ANTIBODY FORMULATION
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
EP2345183A4 (en) Over-the-air test
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
BRPI0909633A2 (pt) anticorpos anti-tyrp1
SMT201700083B (it) Anticorpi monoclonali
DE112008003988A5 (de) Abstandsmesssystem
BRPI0817427A2 (pt) Anticorpo anti-bst2
EP2280284A4 (en) Biosensor